12 July 2021 |

EryDel Announces Top-line Results from Phase 3 ATTeST Trial

BRESSO, JULY 12th 2021 – EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology announced today topline results from its Phase 3 ATTeST clinical trial in patients with Ataxia Telangiectasia (AT), a devastating neurological disease for which there is no approved therapy.

24 April 2018 |

EryDel raises €26,5 Million in financing

Innogest participates in the round led by Sofinnova Partners. Funds will be used to accelerate the company’s international development and complete the registrational Phase III clinical trial of its lead product EryDex

06 March 2017 |

EryDel announces start of ATTEST, Pivotal Phase III Trial in Ataxia Telangiectasia

EryDel SpA, a biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study, a pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of EDS in patients with A-T